CELC Celcuity: Company Short-Term Debts

Celcuity Inc. is advancing cancer diagnostics through alliances with pharmaceutical behemoths, creating synergy in the selection of targeted drugs. The business relies on the analysis of live cells in US centers to personalize therapy. The amount of the company's current liabilities on the GURU.Markets chart reflects a trend where the current metric equals 0.00, although high R&D expenses and the absence of mass testing are constraining operational growth.

To select high-quality assets, an investor must evaluate liquidity through the lens of short-term liabilities, which aggregate all debts with a maturity of up to one year. For Celcuity Inc., which is developing a targeted therapy platform, this calculation determines financial stability during drug commercialization, allowing current borrowed funds to serve as a gauge for the balance between debt load and return on equity.